Nara Capital
VC Fund
Barcelona, Spain
Nara Capital is a VC fund in Barcelona focused on Life Science and Biotechnology. As asset managers, we invest on behalf of third parties. Our fear of losing their money is greater than the fear of losing an opportunity. Our investment style consists of value orientation, specialization and trust, applying our investment criteria in a disciplined way. We invest to transform the companies into industry leaders. With a hands-onapproach, Nara invests in assets enhancing its value with a long-term view. We are a highly experienced team with the patience and tenacity required to see deals through, committing our own money. We create value in a sustainable way, investing in a responsible way to generate a positive impact on the community. We analyze each investment in detail in order to create shared value for our investors, partners, customers, suppliers and workers.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 30%
Last updated:
For AI agents: llms.txt
Industries Nara Capital invests in
Stages Nara Capital invests in
Countries Nara Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $394k–$7.3M
- Venture - Series Unknown
- $1.9M–$3.3M
Investment Focus
Industry
- Life Science 4 (40%)
- Biotechnology 4 (40%)
- Medical 2 (20%)
- Health Care 2 (20%)
- Medical Device 2 (20%)
Stage
- Seed 5 (50%)
- Venture - Series Unknown 2 (20%)
- Series A 1 (10%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Josep Magdalena
Founder and Managing Partner
|
Founder and Managing Partner | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Neboda is a science and technology that aims to transform agriculture into a more sustainable, competitive, and appealing business while also producing a better and healthier product. | $393.8K / Seed / Sep 17, 2025 | ||
| MiMARK specializes in developing in vitro diagnostic solutions to improve the management of gynecological malignancies. The company envisions the gynecological fluid as the next step in liquid biopsy in gynecology. MiMARK 's first objective is to improve endometrial cancer diagnosis. | $393.8K / Seed / Sep 17, 2025 | ||
| Aortyx is a pioneer company founded by researchers from the IQS School of Engineering and the Hospital Clínic de Barcelona that aims at providing a new generation of endovascular devices to treat vascular diseases. Our technology focuses on tissue regeneration by mimicking the aorta biomechanical environment. It provides a suitable milieu for cellmigration and proliferation in a bioresorbable platform that minimizes differences with the natural dynamics of the aorta. | $16M / Series A / Jun 12, 2025 | ||
| Heecap is a non-invasive, tailored electrostimulation technology that maintains respiratory muscle strength in these patients. | $2.9M / Seed / Dec 09, 2024 | ||
Gyala Therapeutics
|
Gyala Therapeutics is focused on developing new CAR-T therapies for treating hematological malignancies. CAR-T (chimeric antigen receptor T cells) is a type of gene therapy in which T lymphocytes -a type of white blood cells that play a key role in immune responses- are extracted from the patient and modified to attack tumour cells. T lymphocytesare obtained through apheresis (a technique that allows separation of blood components) and genetically reprogrammed with a receptor that binds to a tumor factor. When these cells are transduced back to the patient, they are to specifically recognize tumour cells and attack them. Several types of CAR-T cells have demonstrated efficacy in the treatment of leukemias and B cell lymphomas. | $3.3M / Venture - Series Unknown / Oct 14, 2024 | |
| Affirma Biotech is a developer of host-directed drugs as broad-spectrum treatments for chronic and severe infectious diseases. The company utilizes host-directed therapy strategies to interfere with host cell factors that are required by a pathogen for replication or persistence. The company engages in the discovery and development of newanti-infective drugs via immunomodulation. | $1.9M / Venture - Series Unknown / Feb 01, 2024 | ||
| MiMARK specializes in developing in vitro diagnostic solutions to improve the management of gynecological malignancies. The company envisions the gynecological fluid as the next step in liquid biopsy in gynecology. MiMARK 's first objective is to improve endometrial cancer diagnosis. | $4.2M / Seed / Nov 27, 2023 | ||
| OneChain Immunotherapeutics is a spin-off Company from Instituto de Investigación contra la Leucemia Josep Carreras and ICREA, that aims to develop CAR-T candidates against different antigens as a treatment for hematological malignancies based on the know-how of Dr. Pablo Menéndez. | $7.3M / Seed / Jun 22, 2023 | ||
| MiMARK specializes in developing in vitro diagnostic solutions to improve the management of gynecological malignancies. The company envisions the gynecological fluid as the next step in liquid biopsy in gynecology. MiMARK 's first objective is to improve endometrial cancer diagnosis. | $1.1M / Seed / Jun 08, 2023 | ||
| Diagnostic of preterm birth risk and induction labor success probabilities through the use of torsional ultrasound technology | $1.9M / Seed / Feb 15, 2023 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Nara Capital invest in?
Nara Capital invests primarily in Life Science, Biotechnology and Medical startups, most often at Seed and Venture - Series Unknown stage. Most of the 10 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Nara Capital's check size?
Nara Capital typically joins rounds of $394k–$7.3M at Seed and $1.9M–$3.3M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Nara Capital participates in.
How do I contact Nara Capital?
Public channels for Nara Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Nara Capital?
The team at Nara Capital includes Josep Magdalena (Founder and Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
